myeloid leukemia (Cancer)
Information
- Disease name
- myeloid leukemia
- Disease ID
- DOID:8692
- Description
- "A leukemia that is located_in myeloid tissue." [url:http\://en.wikipedia.org/wiki/Myeloid_leukemia]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04714372 | Active, not recruiting | Phase 1 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | November 3, 2021 | December 15, 2025 |
| NCT00001748 | Completed | Phase 1 | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | June 1998 | May 2000 |
| NCT00114764 | Completed | Phase 2 | Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) | March 2003 | August 2004 |
| NCT00001637 | Completed | Phase 2 | Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults | September 29, 1997 | December 28, 2016 |
| NCT00422890 | Completed | Phase 3 | Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®) | January 2007 | |
| NCT00497991 | Completed | Phase 1 | Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia | May 2006 | April 2010 |
| NCT00521664 | Completed | Phase 3 | A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups | September 2004 | September 2010 |
| NCT01380756 | Completed | Phase 1 | Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | October 4, 2011 | September 4, 2014 |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01779882 | Completed | N/A | Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT | January 2013 | January 6, 2018 |
| NCT02719821 | Completed | N/A | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation | March 2016 | June 2, 2017 |
| NCT02763475 | Completed | Phase 2 | NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents | May 2016 | August 2020 |
| NCT02955043 | Completed | N/A | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | December 22, 2016 | October 26, 2018 |
| NCT03613727 | Completed | Phase 2 | Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients | October 1, 2018 | October 6, 2022 |
| NCT04628338 | Completed | Early Phase 1 | IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation | March 8, 2021 | October 30, 2023 |
| NCT05363488 | Completed | Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland | October 8, 2021 | October 8, 2021 | |
| NCT06429449 | Not yet recruiting | Phase 1 | Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | December 2024 | November 2027 |
| NCT05787951 | Not yet recruiting | Frequency and Risk Factors of Acute Myeloid Leukemia | May 1, 2023 | August 1, 2025 | |
| NCT05035706 | Recruiting | Early Phase 1 | Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors | June 30, 2021 | April 30, 2026 |
| NCT05871008 | Recruiting | N/A | Integrated Actionable Aging Assessment for Cancer Patients Pilot | March 1, 2024 | December 2026 |
| NCT06130579 | Recruiting | Phase 2 | Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT | January 1, 2024 | June 30, 2025 |
| NCT04260022 | Recruiting | Phase 1 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | January 9, 2020 | January 31, 2024 |
| NCT06235801 | Recruiting | Phase 1/Phase 2 | A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia | May 22, 2024 | October 1, 2029 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT00126893 | Terminated | Phase 1 | Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia | October 2005 | September 2006 |
| NCT01643603 | Terminated | Phase 1 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | May 2012 | October 9, 2018 |
| NCT00543972 | Terminated | Phase 1 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | September 2007 | August 2008 |
| NCT00887926 | Terminated | Phase 1 | Study of IMC-EB10 in Participant With Leukemia | June 2009 | August 2010 |
| NCT00967343 | Terminated | Phase 2/Phase 3 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | August 2009 | February 2012 |
| NCT01066338 | Unknown status | Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype | February 2010 | ||
| NCT03659084 | Unknown status | Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell Transplantation | April 2016 | April 2020 | |
| NCT02489929 | Unknown status | N/A | Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine | August 2015 | March 2019 |
| NCT03638206 | Unknown status | Phase 1/Phase 2 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | March 1, 2018 | March 1, 2023 |
| NCT01066286 | Unknown status | Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia | February 2010 | ||
| NCT00111345 | Unknown status | Phase 2/Phase 3 | Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | March 2004 | March 2017 |
| NCT05309018 | Withdrawn | Implantation of an Advanced Practice Nurse in the Complex Care Pathway of Patients With AML | May 15, 2024 | December 15, 2024 |
- Disase is a (Disease Ontology)
- DOID:1240
- Cross Reference ID (Disease Ontology)
- GARD:8226
- Cross Reference ID (Disease Ontology)
- ICD10CM:C92
- Cross Reference ID (Disease Ontology)
- ICD9CM:205
- Cross Reference ID (Disease Ontology)
- ICDO:9860/3
- Cross Reference ID (Disease Ontology)
- MESH:D007951
- Cross Reference ID (Disease Ontology)
- NCI:C3172
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:269631008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023470
- Exact Synonym (Disease Ontology)
- leukaemia myelogenous
- Exact Synonym (Disease Ontology)
- leukemia myelogenous
- Exact Synonym (Disease Ontology)
- myeloid granulocytic leukaemia
- Exact Synonym (Disease Ontology)
- myeloid granulocytic leukemia
- Exact Synonym (Disease Ontology)
- myeloid leukaemia
- Exact Synonym (Disease Ontology)
- Non-Lymphocytic Leukemia
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012324